Some clinical studies and recent reviews suggest that oral glutathione may contribute to brightening or melasma-related improvement in certain contexts, often around the 250 to 500 mg per day range, but the body of evidence is still relatively small and not as robust as the marketing often implies
The cardiorenal effects of both GLP-1RA and SGLT-2 inhibitors can be summarized as follows: GLP-1RA have moderate benefits on MACE (major cardiovascular events), may reduce all-cause mortality and hospitalization for HF (HHF), and have a robust effect in reducing the incidence of macroalbuminuria [12]
This was demonstrated in a recent study whereby oral LC supplementation (250 mg for 12 weeks) among patients with PCOS improved total antioxidant capacity (TAC), decreased lipid peroxidation and enhanced general and mental health parameters [40]
Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association